eNOS Blocking Peptide
- Known as:
- eNOS Blocking Peptide
- Catalog number:
- 33r-10759
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- eNOS Blocking Peptide
Related genes to: eNOS Blocking Peptide
- Gene:
- NOS3 NIH gene
- Name:
- nitric oxide synthase 3
- Previous symbol:
- -
- Synonyms:
- ECNOS, eNOS
- Chromosome:
- 7q36.1
- Locus Type:
- gene with protein product
- Date approved:
- 1993-08-23
- Date modifiied:
- 2016-10-05
Related products to: eNOS Blocking Peptide
Related articles to: eNOS Blocking Peptide
- Quality standardization of Indian medicinal plants is crucial for confirming their safety, efficiency, and validity in pharmaceutical applications. The current investigation explores ethnopharmacological perspectives of Allium sativum and Syzygium jambolanum through phytochemical screening using HPTLC and LC-MS profiling, and systems-based pharmacology investigation using network pharmacology and molecular docking studies. The results indicated that both plants are enriched in polyphenols, terpenoids, glycosides, etc., responsible for various biological activities. In vitro antioxidant activity demonstrated significant free-radical neutralization potential. HPTLC showed major and minor metabolites at different R values, and LC-MS analysis showed key bioactive substances including ferulic acid, gallic acid, naringenin, catechin, quercetin, and myricetin. The Network pharmacology study identified interactions with key proteins, including IL-1β, TLR4, IL6, NOS3, ABCA1, with prominent interaction of quercetin and kaempferol with the protein IL-1β. The DisGeNET mapping findings point toward their participation in key pathophysiological conditions like inflammation, interstitial inflammation, myofibroblast activation causing tubulointerstitial fibrosis, and microbial infection. The study concludes that A. sativum and S. jambolanum actively play a significant role in inflammation and associated dysfunctions, hence providing novel plant-based therapeutics as A. Sativum and S. jambolanum by highlighting the significance in traditional medicine as well as their potential relevance in contemporary pharmacology. - Source: PubMed
Singh ManjuGaurav Gaur Praveen Kumar - The SGLT2 inhibitor empagliflozin (EMPA) has been found to reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with or without reduced left ventricular ejection fraction, irrespective of diabetes status. The underlying mechanisms remain to be elucidated. Endothelial-to-mesenchymal transition (EndoMT) has been reported to play a pivotal role in the microvascular rarefaction. This study aimed to evaluate the effect of EMPA on angiotensin II (Ang II)-induced left ventricular dysfunction and to explore the underlying mechanism. - Source: PubMed
Shen Dong-LiWang Zi-MuWang Yan-YanXie Zhong-LeiYuan ShuaiQi Bao-ZhenYao ShunCui Xiao-TongSong YuHan Xue-TingGe Jun-BoZhou Jing-Min - Global aging has led to a steady rise in the number of older adults suffering from the first-episode depression with cognitive impairment (FEDCI), which imposes a huge medical and financial burden on patients and their families. The aim of this study was to explore the influence of the NOS3 rs1799983 polymorphism on the FEDCI. - Source: PubMed
Publication date: 2026/02/03
Yin YinaTang LingkaiXia JiaojiaoChang JunxiaoQian MinChen FeifeiLi ShumingGu Xiaoping - This study aims to elucidate the multi-target molecular mechanism of cyanidin-3-O-glucoside (C3G) in treating Type 2 Diabetes (T2DM) through network pharmacology methods. - Source: PubMed
Publication date: 2026/04/08
Yang WenlingWu MeizhenLuo JuanlieLi YaohuaPan XiaojiaoTian Hui - RNA interference (RNAi) of the placental glucose transporter SLC2A3 resulted in smaller hypoglycemic fetuses with reduced umbilical artery insulin and glucagon concentrations at mid-gestation (75 days of gestation [dGA]) in sheep. Our current objective was to determine the ramifications of SLC2A3-RNAi throughout gestation, and to assess fetal insulin secretion in response to glucose and arginine challenges. We successfully generated SLC2A3-RNAi (n = 6) and NTS-RNAi (non-targeting sequence) control sheep pregnancies (n = 6). Near-term they underwent surgical catheterization followed by in vivo metabolic studies at 133 ± 2 dGA. A baseline metabolic study, which included assessment of uterine and umbilical blood flow rates, was followed by a square-wave hyperglycemic clamp of the fetus (GSIS), followed by infusion of an arginine bolus to assess maximal fetal insulin secretion. The baseline metabolic study determined that uterine glucose uptake (mmol/min) was reduced 29% (P = 0.03), as was placental glucose utilization by 40% (P = 0.05), but umbilical glucose uptake was not impacted in SLC2A3-RNAi pregnancies. By contrast, amino acid carbon uptake/kg of uterus increased 76%, as did placental utilization of amino acid carbon (P = 0.09), indicating placental compensation supported by increased mRNA concentrations of NOS3, IGF2, IGF1R and IGF2R (P ≤ 0.05 to ≤ 0.10). Unlike the findings at 75 dGA, near-term fetal body and pancreas weights were no longer significantly (P ≥ 0.10) impacted by SLC2A3-RNAi. While baseline umbilical artery concentrations of glucose and insulin were not different (P ≥ 0.10), two-way ANOVA revealed a significant (P ≤ 0.01) SLC2A3-RNAi treatment effect during GSIS and arginine stimulated insulin secretion (ASIS), demonstrating significant enhancement of fetal insulin secretion capacity. In summary, placental compensatory mechanisms appeared to rescue fetal growth and umbilical glucose concentrations between mid-gestation and near-term. Decreasing placental glucose utilization while increasing amino acid utilization may be a mechanism aiding recovery of glucose transfer to the fetus. While microvillous glucose uptake to the placenta appears to be rate-limiting to fetal growth and development early in gestation, placental glucose transfer and fetal growth are rescued later in gestation. However, increased nutrient stimulated fetal insulin secretion persists near-term, as a possible sequela of the earlier impacts. - Source: PubMed
Publication date: 2026/04/10
Kennedy Victoria CTanner Amelia RLynch Cameron SWinger Quinton ARozance Paul JAnthony Russell V